A 20-Year-Old Antidepressant Just Did What No Drug Has Ever Been Approved to Do for Meth

Say the sentence plainly, because it’s the one that matters most here: there is no FDA-approved medication for methamphetamine use disorder. Not one. Opioid use disorder has buprenorphine, methadone, naltrexone. Alcohol use disorder has naltrexone, acamprosate, disulfiram. Methamphetamine, involved in a rising share of the polysubstance overdose deaths driving Arizona’s numbers this year, has nothing with an FDA label on it — only off-label attempts and behavioral interventions like contingency management, a structured incentive program now Medicaid-covered in five states via CMS 1115 waivers, which works but requires exactly the kind of staffing, tracking infrastructure, and sustained funding that many programs — especially in states like Arizona that haven’t yet applied for a waiver — simply don’t have.

A drug that already sits in every pharmacy just gave methamphetamine treatment its best pharmacological signal in years — and it’s not a new drug at all.

A randomized clinical trial across six outpatient treatment centers in Australia, published in JAMA Psychiatry, tested mirtazapine — a generic antidepressant on the market since the 1990s, cheap, widely available, already understood by every prescriber in the country — against placebo in adults with methamphetamine use disorder. At three months, participants on mirtazapine used methamphetamine on roughly two fewer days per month than the placebo group. Read quickly, that sounds unimpressive. Read against the actual baseline — nothing — it’s one of the only statistically significant pharmacotherapy results this field has produced.

Here’s the caveat that has to travel with that number, because burying it would be its own kind of dishonesty: two fewer days a month is a modest effect, not a cure, and it was measured over twelve weeks in a controlled trial setting that doesn’t map cleanly onto how someone’s use actually looks outside a study protocol. The trial also found more drowsiness and weight gain in the mirtazapine group, side effects that matter to whether someone actually stays on a medication once no one’s tracking their adherence anymore. This is not a breakthrough with an asterisk. It’s a real, small, honestly reported result, and the honesty is exactly why it’s worth taking seriously — a field this starved for options doesn’t need another overhyped headline, it needs signals it can build on.

What makes the timing notable is that it’s not arriving alone. Researchers at the University of Florida, led by Habibeh Khoshbouei, recently identified a biological pathway linking methamphetamine’s dopamine surges to TNF-alpha, an inflammation-regulating protein — a preclinical, animal-and-cell-level finding, years from anything a patient could take, but a genuinely new mechanistic target in a field that has mostly been repurposing drugs built for other disorders and hoping they transfer. “Unlike alcohol or opioids, there currently is no medicinal therapeutic approach for methamphetamine addiction,” Khoshbouei has said of the gap her lab is trying to close.

Put the two findings side by side and the shape of the actual problem comes into focus. It isn’t that methamphetamine addiction is biologically unreachable — dopamine pathways, inflammation signaling, existing antidepressants that happen to touch the right receptors: there’s real science to work with. It’s that the incentive structure for chasing it has been almost nonexistent, because a fifteen-dollar generic that shows a modest effect in a publicly funded Australian trial isn’t the kind of result that attracts the private capital a novel-compound moonshot does. Mirtazapine will not be patented for this indication. No company stands to make outsized returns proving what this trial just showed. That’s precisely why a public health system, not a pharmaceutical pipeline, was the one that ran the study — and why the next step, if there is one, will depend on public funding and prescriber willingness rather than a marketing budget.

For a clinician sitting across from a patient using methamphetamine today, this isn’t a directive to start prescribing off-label mirtazapine tomorrow without more data — the effect size is real but small, and off-label prescribing decisions belong in a conversation with the patient about what a modest reduction in use-days actually means for their specific situation. What it is: the first honest evidence in years that this use disorder is not permanently outside pharmacology’s reach. Contingency management remains the closest thing the field has to a standard of care for stimulant use disorder precisely because nothing pharmacological has cleared this bar before. Mirtazapine is not a replacement for that. It might, eventually, be a companion to it.

Contingency management remains the closest thing the field has to a standard of care for stimulant use disorder precisely because nothing pharmacological has cleared this bar before.